| Literature DB >> 32851189 |
Jing Qin1, Chong You2, Qiushi Lin2, Taojun Hu3, Shicheng Yu4, Xiao-Hua Zhou2,5,6.
Abstract
We have proposed a novel, accurate low-cost method to estimate the incubation-period distribution of COVID-19 by conducting a cross-sectional and forward follow-up study. We identified those presymptomatic individuals at their time of departure from Wuhan and followed them until the development of symptoms. The renewal process was adopted by considering the incubation period as a renewal and the duration between departure and symptoms onset as a forward time. Such a method enhances the accuracy of estimation by reducing recall bias and using the readily available data. The estimated median incubation period was 7.76 days [95% confidence interval (CI): 7.02 to 8.53], and the 90th percentile was 14.28 days (95% CI: 13.64 to 14.90). By including the possibility that a small portion of patients may contract the disease on their way out of Wuhan, the estimated probability that the incubation period is longer than 14 days was between 5 and 10%.Entities:
Mesh:
Year: 2020 PMID: 32851189 PMCID: PMC7428324 DOI: 10.1126/sciadv.abc1202
Source DB: PubMed Journal: Sci Adv ISSN: 2375-2548 Impact factor: 14.136
Estimates for the incubation periods of SARS, MERS, and COVID-19.
NA, not available.
| Mean (SD) or | Hong Kong | Saudi Arabia | Wuhan ( |
| Beijing ( | South Korea | Mainland China | |
| Taiwan ( | South Korea | Mainland China | |
| Hong Kong | Saudi Arabia | Global ( | |
| Mainland China | South Korea | Global ( | |
| Singapore ( | |||
| Hong Kong | |||
| Median or | Hong Kong, | South Korea | Mainland China |
| Middle East | Global ( | ||
| South Korea | |||
| Percentiles | Mainland | NA | Mainland |
| Hong Kong, | Wuhan, 95% | ||
| Singapore, 95% | Mainland | ||
| Mainland | Global, 2.5% ( | ||
| Hong Kong, | Global, 97.5% | ||
| Mainland |
Fig. 1Illustration of our cross-sectional and forward follow-up study.
Backward and incubation periods are not observed, while Wuhan departure and forward time are observed.
Comparison between the demographic characteristics of patients with COVID-19 in the studying cohort and all publicly available cases collected as of 15 February 2020.
| 0–19 | 17 (3.7) | 126 (3.2) | 24 (4.0) | 180 (4.2) | 0 | 3 |
| 20–39 | 189 (40.9) | 1250 (32.2) | 292 (48.3) | 1508 (35.0) | 1 | 48 |
| 40–59 | 195 (42.2) | 1667 (43.0) | 226 (37.4) | 1843 (42.8) | 0 | 57 |
| 60–79 | 60 (13.0) | 749 (19.3) | 62 (10.2) | 701 (16.3) | 0 | 40 |
| ≥80 | 1 (0.2) | 85 (2.2) | 1 (0.2) | 78 (1.8) | 0 | 8 |
| No information | 6 | 244 | 9 | 287 | 0 | 4089 |
*Number (%). The percentages do not take missing data into account.
Fig. 2Histogram and estimated probability density functions for the time from Wuhan departure to symptoms onset, i.e., forward time.
Results of our model based on different choices of π.
| 1.97 | 1.93 | 1.89 | 1.81 | |
| 0.11 | 0.11 | 0.11 | 0.12 | |
| Mean | 8.29 | 8.01 | 7.75 | 7.32 |
| 5% | 2.07 | 1.93 | 1.81 | 1.60 |
| 25% | 4.97 | 4.73 | 4.51 | 4.14 |
| Median | 7.76 | 7.47 | 7.19 | 6.73 |
| 75% | 11.04 | 10.7 | 10.38 | 9.86 |
| 90% | 14.28 | 13.92 | 13.59 | 13.04 |
| 95% | 16.32 | 15.95 | 15.62 | 15.07 |
| 99% | 20.31 | 19.94 | 19.62 | 19.1 |
| 99.9% | 24.95 | 24.6 | 24.33 | 23.89 |
| −Log | 2843.00 | 2843.21 | 2843.57 | 2844.96 |